NTNaoto Tamura

Naoto Tamura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Naoto Tamura has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • HLA-B*46 associates with psoriasis susceptibility

    by Kyoko Ikumi, Shigeto Kobayashi, Naoto Tamura, Hisashi Inoue, Emi Nishida, Akimichi Morita

  • The synovial grade corresponding to clinically involved joints and a feasible ultrasound-adjusted simple disease activity index for monitoring rheumatoid arthritis

    by Yusuke Yamada, Michihiro Ogasawara, Misa Gorai, Yuko Matsuki, Go Murayama, Nagachika Sugisaki, Takuya Nemoto, Seiichiro Ando, Kentaro Minowa, Souichiro Nakano, et al.

    Objectives: To determine which grade of ultrasound (US) synovitis corresponds to clinically involved joints in rheumatoid arthritis (RA) and develop a new US-adjusted composite measure. Methods: Clinical and US examinations were performed on 137 RA patients (28 joints). Synovial effusion, hypertrophy, and blood flow were semi-quantitatively graded from 0 to 3 using grey scale (GS) and power Doppler (PD) modes. We calculated US-adjusted simple disease activity index (SDAI) and assessed feasibility, and external validity by comparing with erythrocyte sedimentation rate (ESR), and modified health assessment questionnaires (MHAQ). Results: GS ≥2 and PD ≥0 corresponds to clinically swollen joints, and GS ≥2 and PD ≥1 corresponds to tender joints. The US-adjusted SDAI showed the highest correlation when US-determined swollen joints were defined as PD ≥2 with ESR, and GS ≥3 and PD ≥2 with MHAQ. A feasible US-adjusted SDAI examining only clinically involved joints still showed a higher correlation with ESR and MHAQ than SDAI. Conclusion: Our composite measure complemented by US only for clinically involved joints is feasible and reliable for monitoring disease activity.


  • Predictive grade of ultrasound synovitis for diagnosing rheumatoid arthritis in clinical practice and the possible difference between patients with and without seropositivity

    by Kentaro Minowa, Michihiro Ogasawara, Go Murayama, Misa Gorai, Yusuke Yamada, Takuya Nemoto, Yuko Matsuki, Nagachika Sugisaki, Seiichiro Ando, Takayuki Kon, et al.

    Ultrasound findings contributed to RA diagnosis in clinical practice. The contributing factors are different in the presence or absence of seropositivity, and ultrasound complementation was particularly useful in seronegative RA patients.


  • Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan

    by Shinsuke Yasuda, Tatsuya Atsumi, Sanae Shimamura, Kota Ono, Keiju Hiromura, Kenei Sada, Masaaki Mori, Syuji Takei, Yasushi Kawaguchi, Naoto Tamura, et al.

    Mycophenolate mofetil (MMF) is used as one of the standard induction/maintenance protocols for lupus nephritis (LN). However, MMF has not been approved for treating LN in any country, resulting in worldwide off-label use of this immunosuppressant. In order to clarify the real-world use of MMF as a treatment for LN in Japan, Japan College of Rheumatology surveyed the use of MMF in daily clinical practice.Adult patients with LN who visited enrolled hospitals from October 2008 to September 2013 were surveyed for the initial, maximum, and maintenance doses of MMF. The safety and efficacy of MMF were retrospectively evaluated.One hundred and thirty-seven LN patients including 116 females were enrolled. The median of initial, maximum, and maintenance doses of MMF were 1.0 g/day, 1.5 g/day, and 1.0 g/day, respectively. Sixty-one adverse events were reported in 39 patients during the follow-up period. Median urine protein level decreased from 1.89 g/gCr to 0.21 g/gCr, meanC3 level increased from 66.4 mg/dl to 80.3 mg/dl, and median anti-DNA antibody titer decreased from 40.6 IU/ml to 10.6 IU/ml.MMF was commonly used for the treatment of adult LN patients with acceptable efficacy and safety in Japan.


  • Predictive value of bone destruction and duration of clinical remission for subclinical synovitis in rheumatoid arthritis patients

    by Nao Tokai, Michihiro Ogasawara, Misa Gorai, Yuko Matsuki, Yusuke Yamada, Go Murayama, Nagachika Sugisaki, Takuya Nemoto, Seiichiro Ando, Kentaro Minowa, et al.

    Objectives. Treatment for rheumatoid arthritis (RA) should aim to achieve full remission. The aim of this study was to investigate predictors of persistent subclinical synovitis and whether longer clinical remission is effective in reducing subclinical synovitis. Methods. Forty-four RA patients who achieved DAS28ESR clinical remission for at least 3 months were enrolled in this study and underwent ultrasound examination of 22 joints (bilateral proximal interphalangeal joints, metacarpophalangeal joints, and wrists); bilateral hand X-ray; and blood examination. The severity of synovial effusion, synovial hypertrophy, and blood flow were semi-quantitatively graded from 0 to 3 using gray-scale (GS) and power Doppler (PD) modes. Results. Among patients with DAS28ESR-defined clinical remission, 59.1% (26/44) demonstrated residual synovitis (≥ PD1) in at least one joint. Genant-modified total Sharp score (TSS) demonstrated the highest statistical difference between patients with and without residual subclinical synovitis (p = 0.0057), and full remission was only observed in patients with low TSS. A nonsignificant trend for decreased residual synovitis with longer sustained clinical remission was also observed (p = 0.724). Conclusion. Residual synovitis can persist during clinical remission, particularly in patients with progressive bone destruction. Early treatment and longer sustained clinical remission prior to bone destruction are critical for full remission.


    • 17 October 2013
      • Vol. 32  (1) , 54-60

    Can routine clinical measures predict ultrasound-determined synovitis and remission in rheumatoid arthritis patients?

    by Takuya Nemoto, Michihiro Ogasawara, Yuko Matsuki, Go Murayama, Yusuke Yamada, Nagachika Sugisaki, Seiichiro Ando, Kentaro Minowa, Takayuki Kon, Kurisu Tada, et al.

    The purpose of this study was to determine if routine clinical measures can predict the presence and severity of ultrasound synovitis in rheumatoid arthritis (RA) patients. Bilateral 1-5 MCP (metacarpopharangeal) and wrist joints were examined using power Doppler (PD) ultrasound (US). Correlations between PD scores and routine clinical measures of RA - swollen joint count (SJC), tender joint count, patient's global assessment (GA), physician's GA, CRP, ESR, MMP-3, RF and anti-CCP antibody - were determined and used to identify significant predictors of PD score. Clinical measures were then compared between two groups (patients with and without PD) and analysed using multiple logistic regression, to derive a model that predicted the absence of PD signals. SJC was the most significant predictor of PD score (R2 = 0.4566, p value <0.0001), but was an inadequate predictor of PD signal remission. However, the combination of Steinbrocker's stage I or II (odds ratio [OR] 9.23, p=0.0049), SJC=0 in 1-5 MCP and wrist joints on both sides (OR 6.60, p=0.0039), and SDAI (or CDAI) remission (OR 5.06, p=0.0450) had a positive predictive value of 100%, predicting the absence of PD signals in all study patients meeting the 3 criteria. PD score and absence of PD signals can be predicted using routine clinical measures. When used in combination, Steinbrocker's stage, SJC and SDAI (or CDAI) can estimate disease activity and identify patients likely to have synovitis and requiring US.


    • 27 May 2013
      • Vol. 31  (4) , 506-14

    Clinical miscount of involved joints denotes the need for ultrasound complementation in usual practice for patients with rheumatoid arthritis.

    by Go Murayama, Michihiro Ogasawara, Takuya Nemoto, Yusuke Yamada, Seiichiro Ando, Kentaro Minowa, Takayuki Kon, Kurisu Tada, Masakazu Matsushita, Ken Yamaji, et al.

    Ultrasound (US) examination can visualise and clarify involved joints anatomically in patients with rheumatoid arthritis (RA), and it enables physicians to verify the accuracy of clinical assessments of involved joints. Here, we studied the practical 'miscount'- calculated by subtracting US-determined involved joint count from clinically determined involved joint count - and analysed possible contributing factors for increased miscount. The study population consisted of 137 patients with RA. Physical joint examination was performed by 3 assessors with different levels of experience in rheumatology, followed by US joint examination. Clinical and US examinations were performed on 28 joints (proximal interphalangeal, metacarpophalangeal, wrist, elbow, shoulder, and knee on both sides). Miscount was calculated for all patients, and multivariate analysis was conducted on possible contributing factors for miscount, including age, sex, body mass index, disease duration, Steinbrocker stage, erythrocyte sedimentation rate (ESR), C-reactive protein level, patient global assessment (GA), evaluator GA, matrix metalloproteinase-3 level, and power Doppler (PD) score. A high variability in concordance rate among the joint sites was observed among the 3 assessors. The average miscount was 1.07 (SD, 5.19; range, 18 to -11). ESR and patient GA were determined as significant contributing factors for false-positive miscount, whereas PD score and age were significant factors for false-negative miscount. In addition to the condition of the involved joint distribution and the assessor's clinical examination skills, the patients' background can also lead to increased miscount. Assessors should be blinded to patients' background information, and US complementation should be included in usual clinical joint examinations.


  • Recent trends in use of nonbiologic DMARDs and evaluation of their continuation rates in single and dual combination therapies in rheumatoid arthritis patients in Japan

    by Michihiro Ogasawara, Michiaki Kageyama, Makio Kusaoi, Shin Onuma, Takayuki Kon, Fumio Sekiya, Kaoru Sugimoto, Ran Matsudaira, Masakazu Matsushita, Kurisu Tada, et al.

    Objective We aim to examine changes in usage of nonbiologic, disease-modifying antirheumatic drugs (DMARDs) and evaluate their continuation rates in Japan. Methods We analyzed DMARD treatment data for 3,734 patients with rheumatoid arthritis (RA) from 1998 to 2009 at Juntendo Hospital in Tokyo, Japan. The DMARD usage rate per month was determined to evaluate RA treatment history in the last decade. We also evaluated continuation rates of nonbiologic DMARDs in single and combination therapies and number of nonbiologic DMARD combination therapies used in each patient. Results We found that nonbiologic DMARD usage has dramatically changed in the last decade, with the most commonly used DMARD shifting from bucillamine to methotrexate (MTX). MTX showed the highest continuation rate; however, much lower continuation rate was observed when used alone rather than in combination treatments. Further, MTX was also used in the highest number of different combination therapies for a particular patient. Conclusions These findings indicate that single MTX treatment may be unable to keep patients in clinical remission or lower disease activity compared with several combination therapies. Recent change in permitted maximum dosage of MTX from 8 to 16 mg/week may improve its efficacy and continuation rate in treating Japanese RA patients.

  • A Case of Disseminated Nocardiosis Complicated with Adult Onset Still's Disease.

    by Ayako Suzuki, Yoshiyuki Abe, Takashi Watanabe, Michihiro Ogasawara, Hirofumi Amano, Naoto Tamura, Yoshinari Takasaki

    50歳,女性,2008年5月成人Still病と診断された.同年10月prednisolone(PSL):0.65mg/kg内服中,発熱,背部の皮下膿瘍を認め,肺,脳実質内に空洞を伴い多発する浸潤影が出現,また血液と皮下膿瘍からNocardia farcinicaが同定され播種性ノカルジア症と診断した.sulfamethoxazol-trimethoprim(ST合剤)による治療を開始したが副作用のため中止,imipenem/cilastatin(IPM/CS),amikacin(AMK)を6週間投与したところ病変はほぼ消失した.その後moxifloxacin(MFLX)の内服に切り替え,病変の再燃はない.

  • Open Access

    Two Cases of Refractory Wegeners Granulomatosis Successfully Treated with Rituximab

    by Naoto Tamura, Ran Matsudaira, Mika Hirashima, Makoto Ikeda, Michiko Tajima, Masuyuki Nawata, Shinji Morimoto, Kazuhiko Kaneda, Shigeto Kobayashi, Hiroshi Hashimoto, et al.

    Conventional therapy for Wegeners granulomatosis, steroid and cyclophosphamide, fails to control disease activity in some refractory patients and has treatment-related toxicity. B cell depletion therapy using rituximab, a chimeric anti-CD20 monoclonal antibody, has been shown to be effective for certain autoimmune diseases including antineutrophil cytoplasmic antibody (ANCA) -associated systemic vasculitis. We report two refractory cases of Wegeners granulomatosis: one with bronchial and pulmonary involvement and retroorbital granuloma, the other with retroorbital granuloma and hypertrophic pachymeningitis causing severe headache. Rituximab was effective in both cases, with diminished granuloma and reduced ANCA titers, allowing steroids to be tapered. No adverse effects were detected.